Table 1.
Representation of previous similar clinical cases described in the literature and involving different anti-SARS-CoV-2 therapeutic regimens associated with hematological disease and outcome.
| Author | Diagnosis | Disease related to Covid-19 | Oxygen therapy | Positive period | |
|---|---|---|---|---|---|
| 1 | Helleberg et al (2020) [22] | Chronic lymph. leukemia | Interstitial pneumonia | Yes | 65 days |
| Magyari et al (2022) [21] | B-cell depleted hematological patients | Interstitial pneumonia | Yes | Unknown | |
| 3 | Seki et al (2022) [23] | Non-Hodgkin lymphoma | Interstitial pneumonia | Yes | 60 days |
| 4 | Seki et al (2022) [23] | Multiple myeloma | Interstitial pneumonia | Yes | >30 days |
| 5 | Baldi et al (2022) [13] | Non-Hodgkin lymphoma | Interstitial pneumonia | Yes | 40 days |
| 6 | Graziani et al 2022) [14] | Non-Hodgkin lymphoma | Interstitial pneumonia | Yes | 55 days |
| 7 | Graziani et al (2022) [14] | Non-Hodgkin lymphoma | Interstitial pneumonia | Yes | >50 days |
| 8 | Ford et al (2022) [16] | B-cell acute lymph, leukemia | Interstitial pneumonia | Yes | 120 days |
| Anti-Covid-19 therapeutic regimens | Outcome | Immunosuppressive therapy | Anti-sars-CoV-2 vaccine | |
|---|---|---|---|---|
| 1 | – Remdesivir 10 days i.v. – Remdesivir 10 days i.v. + convalescent plasma i.v. |
Negative | Fludarabina, cyclophosphamide rituximab | Unknown |
| 2 | – Remdesivir 5 days i.v. – convalescent plasma i.v. |
Negative | Rituximab | Unknown |
| 3 | – Sotrovimab i.v. – Remdesivir 5 days i.v.+ Corticosteroids i.v. – Molnupiravir 5 days p.o. + gamma globulin i.v. + corticosteroids i.v. |
Death | CHOP, baricitinib | Yes |
| 4 | – Remdesivir 5 days + sotrovimab i.v. – Corticosteroids i.v. vMolnupiravir 5 days p.o. + sotrovimab i.v. |
Persistent positive | Lenalidomide, dexamethasone | Yes |
| 5 | – Sotrovimab i.v. – Remdesivir 7 days i.v. + Paxlovid 5 days p.o. + corticosteroids i.v. |
Negative | Rituximab | Yes |
| 6 | – Sotrovimab i.v. – Paxlovid 5 days p.o. |
Negative | Obinutuzumab | Unknown |
| 7 | – Sotrovimab i.v. – Remdesivir 5 days i.v. – Paxlovid 5 days p.o. |
Persistent positive | Rituximab | Unknown |
| 8 | – Sotrovimab i.v. – Remdesivir 10 days i.v. – Remdesivir 5 days i.v. + Paxlovid 10 days p.o. + Paxlovid 10 days p.o. (corticosteroids i.v.) |
Negative | Rituximab | Unknown |
This table presents some clinical cases described in the literature with explication of the following details: authors with bibliographic references, diagnosis of patient’s hematological disease, disease related to COVID-19, oxygen-therapy in relation to the presence of respiratory failure, positive time (expressed in days), anti-COVID-19 therapeutic regimens (remdesivir, sotrovimab, corticosteroids, convalescent plasma, nirmatrelvir/ritonavir as Paxlovid, molnupiravir) with reference to the mode of administration (i.v.: intravenous; p.o.: oral), outcome expressed as positivity or negativity to SARS-CoV-2 antigenic or molecular test, immunosuppressive therapy before starting anti-SARS-CoV-2 treatment, and anti-SARS-CoV-2 vaccine (expressed as Yes, Not or Unknown).